Published in Cancer Cell on April 07, 2009
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer (2013) 4.20
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol (2010) 3.86
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 2.46
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med (2010) 2.41
Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2009) 2.35
Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J (2012) 2.21
Retracted Deficiency of G-protein-coupled bile acid receptor Gpbar1 (TGR5) enhances chemically induced liver carcinogenesis. Hepatology (2013) 2.16
Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood (2016) 2.10
IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity (2014) 2.08
Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer (2010) 2.04
Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. Cell Signal (2010) 1.99
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A (2012) 1.94
Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat Commun (2015) 1.79
STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal (2014) 1.79
Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell Div (2010) 1.70
IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One (2013) 1.62
Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol (2012) 1.61
JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab (2012) 1.56
High-fat diet activates pro-inflammatory response in the prostate through association of Stat-3 and NF-κB. Prostate (2011) 1.54
IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res (2010) 1.45
Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene (2013) 1.44
CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. Immunity (2016) 1.44
MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal (2011) 1.42
Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease. J Clin Invest (2017) 1.38
Translational approaches to treatment-induced symptoms in cancer patients. Nat Rev Clin Oncol (2012) 1.38
Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets (2011) 1.38
Radiation induced non-targeted response: mechanism and potential clinical implications. Curr Mol Pharmacol (2011) 1.36
Functional interplay between acetylation and methylation of the RelA subunit of NF-kappaB. Mol Cell Biol (2010) 1.36
NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol Cancer (2010) 1.33
Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells. J Biol Chem (2013) 1.31
PI3K and STAT3: a new alliance. Cancer Discov (2011) 1.31
Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene (2014) 1.30
Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest (2010) 1.28
Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A (2012) 1.26
NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother (2010) 1.25
NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell (2013) 1.25
STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT (2014) 1.24
Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther (2011) 1.22
STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol (2011) 1.18
MicroRNA-124 mediates the cholinergic anti-inflammatory action through inhibiting the production of pro-inflammatory cytokines. Cell Res (2013) 1.15
Unphosphorylated STAT3 modulates alpha 7 nicotinic receptor signaling and cytokine production in sepsis. Eur J Immunol (2010) 1.15
Chronic inflammation in cancer development. Front Immunol (2012) 1.14
The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J Biol Chem (2010) 1.14
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res (2014) 1.13
STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction. Inflamm Bowel Dis (2011) 1.13
Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med (2012) 1.13
Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Front Physiol (2014) 1.10
Age-associated chronic diseases require age-old medicine: role of chronic inflammation. Prev Med (2011) 1.09
Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol (2014) 1.09
A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells. Gastroenterology (2014) 1.09
A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB. BMC Cell Biol (2011) 1.07
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle (2013) 1.06
Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol (2012) 1.04
NF-κB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma. PLoS One (2013) 1.04
STAT3 signaling in pulmonary arterial hypertension. JAKSTAT (2012) 1.04
Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene (2013) 1.03
The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. JAKSTAT (2014) 1.03
IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. Oncogene (2011) 1.03
Essential role of cooperative NF-κB and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma. Oncogene (2012) 1.02
Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther (2010) 1.02
Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol (2013) 1.01
MicroRNAs in colorectal carcinoma - from pathogenesis to therapy. J Exp Clin Cancer Res (2016) 1.00
Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br J Pharmacol (2010) 1.00
The gastrointestinal tumor microenvironment. Gastroenterology (2013) 0.99
CPEB control of NF-kappaB nuclear localization and interleukin-6 production mediates cellular senescence. Mol Cell Biol (2011) 0.98
Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology (2015) 0.98
Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov (2016) 0.98
Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Oncotarget (2014) 0.97
γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br J Pharmacol (2011) 0.97
Effect of silibinin in human colorectal cancer cells: targeting the activation of NF-κB signaling. Mol Carcinog (2011) 0.96
Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci Rep (2015) 0.96
Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Br J Pharmacol (2013) 0.95
Effects of S-adenosylmethionine and methylthioadenosine on inflammation-induced colon cancer in mice. Carcinogenesis (2011) 0.95
Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol (2011) 0.95
Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp. PLoS One (2011) 0.95
Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prev Res (Phila) (2010) 0.95
Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS One (2013) 0.94
The gastrointestinal microbiota and colorectal cancer. Am J Physiol Gastrointest Liver Physiol (2014) 0.94
Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis. Gut (2011) 0.94
IL-6-STAT3 signaling and premature senescence. JAKSTAT (2013) 0.93
Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways. Int J Cancer (2012) 0.93
Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front Immunol (2014) 0.92
The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel) (2014) 0.91
Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor. Cancer Res (2010) 0.91
Pro-survival role of MITF in melanoma. J Invest Dermatol (2014) 0.91
NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age. Expert Rev Neurother (2014) 0.91
A requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF-κB in tumors. Cancer Res (2011) 0.91
Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm (2012) 0.91
B cells promote tumor progression via STAT3 regulated-angiogenesis. PLoS One (2013) 0.90
The G-protein-coupled bile acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell proliferation and migration through antagonizing STAT3 signaling pathway. Oncotarget (2015) 0.90
Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. FASEB J (2011) 0.90
Lipocalin 2 is a regulator of macrophage polarization and NF-κB/STAT3 pathway activation. Mol Endocrinol (2014) 0.89
Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer. Trends Parasitol (2014) 0.89
Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol Cancer (2014) 0.89
Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops. Curr Signal Transduct Ther (2013) 0.88
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res (2014) 0.88
NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol (1998) 21.48
Stat3 as an oncogene. Cell (1999) 17.39
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol (2005) 13.98
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (1994) 11.33
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 7.78
Transcription factors as targets for cancer therapy. Nat Rev Cancer (2002) 7.27
Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol (2004) 6.88
Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science (2001) 6.79
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell (2009) 6.26
IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell (2004) 6.13
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J (2002) 4.91
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 4.56
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell (2005) 3.67
Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev (2007) 3.57
NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol (2005) 3.50
STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A (2003) 3.46
Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest (2008) 3.37
CARD11 mediates factor-specific activation of NF-kappaB by the T cell receptor complex. EMBO J (2002) 2.90
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 2.81
STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity (2002) 2.77
NF-kappaB activation: the I kappaB kinase revealed? Cell (1997) 2.73
A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci U S A (2000) 2.64
Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med (Berl) (2003) 1.79
Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther (2004) 1.70
Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer. Oncogene (2004) 1.38
Real time analysis of STAT3 nucleocytoplasmic shuttling. J Biol Chem (2003) 1.38
Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res (2005) 1.37
Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation. FEBS Lett (2001) 1.36
Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle (2004) 1.34
Tip60 is a co-repressor for STAT3. J Biol Chem (2003) 1.30
Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. J Immunol (2003) 1.28
Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J Biol Chem (2001) 1.20
The STAT3 DNA-binding domain mediates interaction with NF-kappaB p65 and inducible nitric oxide synthase transrepression in mesangial cells. J Am Soc Nephrol (2004) 1.17
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 7.45
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res (2002) 5.84
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 4.56
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell (2009) 4.47
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Differential effects of PER2 phosphorylation: molecular basis for the human familial advanced sleep phase syndrome (FASPS). Genes Dev (2006) 3.78
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med (2006) 3.49
Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest (2008) 3.37
Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res (2002) 3.25
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol (2004) 3.24
Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol (2003) 3.12
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res (2009) 3.07
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood (2007) 3.00
Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol (2004) 3.00
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol (2005) 2.96
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 2.81
Stat3 regulates genes common to both wound healing and cancer. Oncogene (2005) 2.80
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 2.54
A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 2.41
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med (2010) 2.41
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res (2006) 2.41
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Vesicular glycolysis provides on-board energy for fast axonal transport. Cell (2013) 2.33
Diagnostic accuracy of magnetic resonance angiography for internal carotid artery disease: a systematic review and meta-analysis. Stroke (2008) 2.33
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28
Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res (2006) 2.11
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther (2004) 2.10
Lipidic pore formation by the concerted action of proapoptotic BAX and tBID. J Biol Chem (2004) 2.06
ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs (2010) 2.03
Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs (2010) 2.01
Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A (2005) 2.00
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
Expression and role of Foxa proteins in prostate cancer. Prostate (2006) 1.96
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res (2007) 1.96
Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev (2005) 1.93
Role of Stat3 in regulating p53 expression and function. Mol Cell Biol (2005) 1.91
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation (2005) 1.79
Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther (2004) 1.70
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene (2005) 1.70
CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology (2015) 1.70